Halozyme inks Enhanze deal with NIH unit in HIV

Halozyme (HALO +1.4%) enters into an agreement with the NIH’s National Institute of Allergy and Infectious Diseases’ Vaccine Research Center aimed at leveraging HALO’s ENHANZE drug delivery technology to develop subcutaneous formulations of broadly neutralizing antibodies against HIV.

First up are early-stage studies to assess the safety, tolerability, dose and pharmacokinetics of the two candidates.

Financial terms are not disclosed.

https://seekingalpha.com/news/3473595-halozyme-inks-enhanze-deal-nih-unit-hiv